Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes):

Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­attempt, rais­es $35M Collection B Financ­ing … The com­pa­ny intends to make use of the funds to advance lead can­di­dates into Section 2b stud­ies in main depres­sive dis­or­der … Professional­ceeds from the financ­ing may also be used to progress the corporate’s arti­fi­cial intel­li­gence-enabled mind bio­mark­er plat­type and launch new clin­i­cal tri­als in areas of excessive unmet med­ical want. Alto will report Section 2a knowledge in ear­ly 2023 and fur­ther antic­i­pates Section 2b knowledge learn­outs by ear­ly 2024.

Led by Amit Etkin, M.D., Ph.D., founder and chief exec­u­tive offi­cer, Alto Neu­ro­science professional­vides a pre­ci­sion psy­chi­a­attempt by devel­op­ing tar­get­ed med­i­cines to assist sufferers get wager­ter. Dif­fer­ences in indi­vid­u­als’ biol­o­gy impression how they reply to deal with­ment. Its Pre­ci­sion Psy­chi­a­attempt Plat­type mea­sures mind bio­mark­ers by ana­lyz­ing EEG activ­i­ty, behav­ioral job per­for­mance, put on­in a position knowledge, genet­ics, and oth­er fac­tors to match every affected person with the correct Alto drug. The corporate’s clin­i­cal-stage pipeline consists of nov­el drug can­di­dates in depres­sion, PTSD, and oth­er males­tal well being con­di­tions, outcome­ing within the broad­est and most-advanced pre­ci­sion psy­chi­a­attempt effort.

The Announcement:

Alto Neu­ro­science Announces $35 Mil­lion Series B Financ­ing (press launch):

Alto Neu­ro­science at this time introduced the clos­ing of a $35 mil­lion Collection B financ­ing led by Lightswitch Cap­i­tal and half­ners of Alkeon Cap­i­tal, with par­tic­i­pa­tion from oth­er new buyers includ­ing Sobra­to Cap­i­tal, Novar­tis Phar­ma AG, Val­or Equi­ty Half­ners, Kori­fy Cap­i­tal, Vine Ven­tures, and Achieve­gels. The financ­ing additionally includ­ed par­tic­i­pa­tion from exist­ing buyers Ape­iron Group, WhatIf Ven­tures, Wind­ham Ven­ture Half­ners, and oth­ers. This spherical brings Alto’s whole fund­ing to $75 mil­lion thus far … In con­junc­tion with the Collection B financ­ing, chief exec­u­tive offi­cer of Lightswitch Cap­i­tal, Christo­pher Cox, and man­ag­ing direc­tor of Alkeon Cap­i­tal, Jeff Chen, Ph.D., have joined the Alto Board of Direc­tors. Addi­tion­al­ly, Bob Baloh, M.D., Ph.D., glob­al head of neu­ro­science on the Novar­tis Insti­tutes for Bio­Med­ical Analysis (NIBR), will be a part of as a board observer.

Information in Context: